Skip to content

BillionToOne, Inc. BLLN Derivative Liability, Current

Derivative Liability, Current at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M
Total equity$505.6M+300%
Total assets$700.7M

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.84B

Profitability

See full
Gross margin70.4%
Operating margin-96.9%
Net margin8.4%
FCF margin-83.4%

Returns & leverage

See full
Debt / equity0.3×
Current ratio10.9×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: BillionToOne, Inc. ’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's derivative liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's derivative liability, current?
BillionToOne, Inc. (BLLN) reported derivative liability, current of $8.92M in Q1 2026.